{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:12:24Z","timestamp":1790665944638,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","award":["ANR 20-SFRI-0012"],"award-info":[{"award-number":["ANR 20-SFRI-0012"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","award":["ANR-10-IDEX-0002"],"award-info":[{"award-number":["ANR-10-IDEX-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","award":["ANR-17-EURE-0023"],"award-info":[{"award-number":["ANR-17-EURE-0023"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","award":["22734"],"award-info":[{"award-number":["22734"]}],"id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.coph.2022.102328","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T16:46:14Z","timestamp":1670690774000},"page":"102328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Therapeutic approaches in different congenital myopathies"],"prefix":"10.1016","volume":"68","author":[{"given":"Charlotte","family":"Gineste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-5862","authenticated-orcid":false,"given":"Jocelyn","family":"Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102328_sref1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.761636","article-title":"A\u00a0systematic review and meta-analysis of the prevalence of congenital myopathy","volume":"12","author":"Huang","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.spen.2011.10.005","article-title":"Core myopathies","volume":"18","author":"Jungbluth","year":"2011","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40478-018-0655-5","article-title":"Dusty core disease' (DuCD): expanding morphological spectrum of RYR1 recessive myopathies","volume":"7","author":"Garibaldi","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.coph.2022.102328_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10974-019-09519-9","article-title":"Nemaline myopathies: a current view","volume":"40","author":"Sewry","year":"2019","journal-title":"J\u00a0Muscle Res Cell Motil"},{"key":"10.1016\/j.coph.2022.102328_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1172-3-26","article-title":"Centronuclear (myotubular) myopathy","volume":"3","author":"Jungbluth","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coph.2022.102328_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/B978-0-444-64076-5.00036-3","article-title":"The genetics of congenital myopathies","volume":"148","author":"Gonorazky","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ajmg.a.62590","article-title":"A\u00a0homozygous CAP2 pathogenic variant in a neonate presenting with rapidly progressive cardiomyopathy and nemaline rods","volume":"188","author":"Gurunathan","year":"2022","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.coph.2022.102328_bib8","first-page":"266","article-title":"Core myopathies - a short review","volume":"39","author":"Topaloglu","year":"2020","journal-title":"Acta Myol"},{"key":"10.1016\/j.coph.2022.102328_sref9","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/hmg\/ddt252","article-title":"Cardiac alpha-actin over-expression therapy in dominant ACTA1 disease","volume":"22","author":"Ravenscroft","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ana.24619","article-title":"Modulating myosin restores muscle function in a mouse model of nemaline myopathy","volume":"79","author":"Lindqvist","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib11","article-title":"Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to Nebulin-deficiency","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102328_bib12","article-title":"Functional characterization of the intact diaphragm in a Nebulin-based nemaline myopathy (NM) model-effects of the fast skeletal muscle troponin activator tirasemtiv","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2022.102328_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jmedgenet-2012-101470","article-title":"Troponin activator augments muscle force in nemaline myopathy patients with Nebulin mutations","author":"de Winter","year":"2013","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.coph.2022.102328_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13395-015-0037-7","article-title":"Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene","volume":"5","author":"de Winter","year":"2015","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.coph.2022.102328_bib15","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/brain\/awt113","article-title":"Deleting exon 55 from the Nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy","volume":"136","author":"Ottenheijm","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.coph.2022.102328_bib16","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1093\/hmg\/dds289","article-title":"Congenital myopathy-causing tropomyosin mutations induce thin filament dysfunction via distinct physiological mechanisms","volume":"21","author":"Ochala","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_bib17","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1113\/jphysiol.2008.153650","article-title":"Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation","volume":"586","author":"Ochala","year":"2008","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.coph.2022.102328_sref18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224467","article-title":"Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy","volume":"14","author":"Lindqvist","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102328_bib19","first-page":"517","article-title":"KLHL40-related nemaline myopathy with a sustained, positive response to treatment with acetylcholinesterase inhibitors","volume":"263","author":"Natera-de Benito","year":"2016","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib20","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ajpath.2016.02.008","article-title":"Treatment with ActRIIB-mFc produces myofiber growth and improves lifespan in the Acta1 H40Y murine model of nemaline myopathy","volume":"186","author":"Tinklenberg","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2022.102328_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jnen\/nly120","article-title":"Myostatin inhibition using ActRIIB-mFc does not produce weight gain or strength in the nebulin conditional KO mouse","volume":"78","author":"Tinklenberg","year":"2019","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/hmg\/ddx431","article-title":"Myostatin inhibition using mRK35 produces skeletal muscle growth and tubular aggregate formation in wild type and TgACTA1D286G nemaline myopathy mice","volume":"27","author":"Tinklenberg","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_bib23","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/brain\/awr274","article-title":"Hypertrophy and dietary tyrosine ameliorate the phenotypes of a mouse model of severe nemaline myopathy","volume":"134","author":"Nguyen","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.coph.2022.102328_bib24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/0883073807309794","article-title":"Dietary L-tyrosine supplementation in nemaline myopathy","volume":"23","author":"Ryan","year":"2008","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29437-z","article-title":"L-tyrosine supplementation does not ameliorate skeletal muscle dysfunction in zebrafish and mouse models of dominant skeletal muscle \u03b1-actin nemaline myopathy","volume":"8","author":"Messineo","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2022.102328_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40478-018-0546-9","article-title":"Testing of therapies in a novel nebulin nemaline myopathy model demonstrate a lack of efficacy","volume":"6","author":"Sztal","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.coph.2022.102328_bib27","first-page":"387","article-title":"Centronuclear myopathies under attack: a plethora of therapeutic targets","volume":"5","author":"Tasfaout","year":"2018","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.coph.2022.102328_bib28","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/hmg\/ddn112","article-title":"AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis","volume":"17","author":"Buj-Bello","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_sref29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007523","article-title":"Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy","volume":"6","author":"Childers","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102328_bib30","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/hmg\/ddt003","article-title":"Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy","volume":"22","author":"Lawlor","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_bib31","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1093\/hmg\/ddx258","article-title":"Expression of the neuropathy-associated MTMR2 gene rescues MTM1-associated myopathy","volume":"26","author":"Raess","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnen\/nly002","article-title":"Intravenous administration of a MTMR2-encoding AAV vector ameliorates the phenotype of myotubular myopathy in mice","volume":"77","author":"Daniele","year":"2018","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.coph.2022.102328_sref33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.15252\/emmm.201707988","article-title":"Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy","volume":"10","author":"Trochet","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coph.2022.102328_bib34","article-title":"Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin","volume":"5","author":"Massana Munoz","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2022.102328_bib35","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1073\/pnas.1808170115","article-title":"Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy","volume":"115","author":"Buono","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2022.102328_sref36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omtn.2019.02.019","article-title":"Allele-specific CRISPR\/Cas9 correction of a heterozygous DNM2 mutation rescues centronuclear myopathy cell phenotypes","volume":"16","author":"Rabai","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.coph.2022.102328_bib37","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1172\/JCI71206","article-title":"Reducing dynamin 2 expression rescues X-linked centronuclear myopathy","volume":"124","author":"Cowling","year":"2014","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.coph.2022.102328_sref38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15661","article-title":"Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice","volume":"8","author":"Tasfaout","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2022.102328_bib39","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.ymthe.2018.02.008","article-title":"Single intramuscular injection of AAV-shRNA reduces DNM2 and prevents myotubular myopathy in mice","volume":"26","author":"Tasfaout","year":"2018","journal-title":"Mol Ther : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.coph.2022.102328_sref40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1866","article-title":"Amphiphysin 2 modulation rescues myotubular myopathy and prevents focal adhesion defects in mice","volume":"11","author":"Lionello","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102328_bib41","first-page":"119","article-title":"BIN1 modulation in\u00a0vivo rescues dynamin-related myopathy","author":"Lionello","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2022.102328_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.nmd.2011.02.012","article-title":"Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies","volume":"21","author":"Robb","year":"2011","journal-title":"Neuromuscul Disord : NMD"},{"key":"10.1016\/j.coph.2022.102328_bib43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00109-013-0994-4","article-title":"Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy","volume":"91","author":"Gibbs","year":"2013","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.coph.2022.102328_bib44","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajpath.2010.10.035","article-title":"Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice","volume":"178","author":"Lawlor","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2022.102328_bib45","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ajpath.2014.03.003","article-title":"Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1\u00a0p.R69C mice","volume":"184","author":"Lawlor","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2022.102328_sref46","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2022.102328_bib47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.omtm.2020.04.022","article-title":"Myostatin: a circulating biomarker correlating with disease in myotubular myopathy mice and patients","volume":"17","author":"Koch","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.coph.2022.102328_bib48","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1172\/JCI86841","article-title":"PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models","volume":"126","author":"Sabha","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2022.102328_bib49","doi-asserted-by":"crossref","first-page":"14432","DOI":"10.1073\/pnas.1604099113","article-title":"Phosphatidylinositol 3-kinase inhibition restores Ca2+ release defects and prolongs survival in myotubularin-deficient mice","volume":"113","author":"Kutchukian","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2022.102328_sref50","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-022-02468-7","article-title":"X-linked myotubular myopathy is associated with epigenetic alterations and is ameliorated by HDAC inhibition","author":"Volpatti","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.coph.2022.102328_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1128\/MCB.01075-12","article-title":"Defective autophagy and mTORC1 signaling in myotubularin null mice","volume":"33","author":"Fetalvero","year":"2013","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coph.2022.102328_bib52","doi-asserted-by":"crossref","first-page":"21288","DOI":"10.1073\/pnas.2003847117","article-title":"Selenoprotein N is an endoplasmic reticulum calcium sensor that links luminal calcium levels to a redox activity","volume":"117","author":"Chernorudskiy","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2022.102328_bib53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.redox.2018.10.017","article-title":"A\u00a0maladaptive ER stress response triggers dysfunction in highly active muscles of mice with SELENON loss","volume":"20","author":"Pozzer","year":"2019","journal-title":"Redox Biol"},{"key":"10.1016\/j.coph.2022.102328_sref54","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/hum.2013.052","article-title":"Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy","volume":"24","author":"Rendu","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coph.2022.102328_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049757","article-title":"Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathy","volume":"7","author":"Loy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102328_bib56","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/ene.13051","article-title":"Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis","volume":"23","author":"Scalco","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00401-020-02150-w","article-title":"Intracellular calcium leak as a therapeutic target for RYR1-related myopathies","volume":"139","author":"Kushnir","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.coph.2022.102328_bib58","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/brain\/aws036","article-title":"Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy","volume":"135","author":"Dowling","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.coph.2022.102328_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6792694","article-title":"Antioxidant treatment reduces formation of structural cores and improves muscle function in RYR1(Y522S\/WT) mice","volume":"2017","author":"Michelucci","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.coph.2022.102328_bib60","doi-asserted-by":"crossref","first-page":"e1434","DOI":"10.1212\/WNL.0000000000008872","article-title":"Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies","volume":"94","author":"Todd","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2022.102328_sref61","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.21644","article-title":"Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment","volume":"65","author":"Arbogast","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2022.102328_sref62","article-title":"A\u00a0chemical chaperone improves muscle function in mice with a RyR1 mutation","volume":"8","author":"Lee","year":"2017","journal-title":"Nat Comput"},{"key":"10.1016\/j.coph.2022.102328_sref63","first-page":"11","article-title":"Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors","author":"Ruiz","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.coph.2022.102328_bib64","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52946","article-title":"Identification of drug modifiers for RYR1-related myopathy using a multi-species discovery pipeline","volume":"9","author":"Volpatti","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.coph.2022.102328_bib65","first-page":"131","article-title":"Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium","author":"van de Locht","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2022.102328_bib66","first-page":"23","article-title":"Silencing of the Ca(2+) channel ORAI1 improves the multi-systemic phenotype of tubular aggregate myopathy (TAM) and stormorken syndrome (STRMK) in mice","author":"Silva-Rojas","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2022.102328_sref67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146036","article-title":"Aerobic training in patients with congenital myopathy","volume":"11","author":"Hedermann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2022.102328_bib68","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12883-020-01725-0","article-title":"Efficacy of a physical activity programme combining individualized aerobic exercise and coaching to improve physical fitness in neuromuscular diseases (I'M FINE): study protocol of a randomized controlled trial","volume":"20","author":"Oorschot","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.coph.2022.102328_sref69","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/hmg\/ddab112","article-title":"Acute and chronic tirasemtiv treatment improves in\u00a0vivo and in\u00a0vitro muscle performance in actin-based nemaline myopathy mice","volume":"30","author":"de Winter","year":"2021","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_bib70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12929-020-00707-1","article-title":"L-Carnitine ameliorates congenital myopathy in a tropomyosin 3 de novo mutation transgenic zebrafish","volume":"28","author":"Hsu","year":"2021","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.coph.2022.102328_bib71","first-page":"852","article-title":"Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models","volume":"5","author":"Dowling","year":"2012","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.coph.2022.102328_sref72","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41467-018-07058-4","article-title":"Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy","volume":"9","author":"Gayi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2022.102328_sref73","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1038\/s41467-018-07057-5","article-title":"Tamoxifen therapy in a murine model of myotubular myopathy","volume":"9","author":"Maani","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2022.102328_bib74","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ymthe.2021.08.006","article-title":"Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes","volume":"30","author":"Silva-Rojas","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.coph.2022.102328_bib75","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.nmd.2014.05.003","article-title":"RYR1-related congenital myopathy with fatigable weakness, responding to pyridostigimine","volume":"24","author":"Illingworth","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102328_bib76","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-2004-821173","article-title":"Pilot trial of salbutamol in central core and multi-minicore diseases","volume":"35","author":"Messina","year":"2004","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.coph.2022.102328_bib77","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1093\/hmg\/ddh285","article-title":"Muscle weakness in a mouse model of nemaline myopathy can be reversed with exercise and reveals a novel myofiber repair mechanism","volume":"13","author":"Joya","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2022.102328_bib78","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mus.20138","article-title":"Myofiber adaptational response to exercise in a mouse model of nemaline myopathy","volume":"30","author":"Nair-Shalliker","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102328_bib79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/dmcn.14365","article-title":"Congenital myopathies: an update","volume":"62","author":"Claeys","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.coph.2022.102328_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00401-012-1024-2","article-title":"Myosinopathies: pathology and mechanisms","volume":"125","author":"Tajsharghi","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.coph.2022.102328_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceca.2018.07.008","article-title":"Gain-of-function mutations in STIM1 and ORAI1 causing tubular aggregate myopathy and Stormorken syndrome","volume":"76","author":"Bohm","year":"2018","journal-title":"Cell Calcium"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:13Z","timestamp":1761461833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222001552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":81,"alternative-id":["S1471489222001552"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102328","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches in different congenital myopathies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102328"}}